Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Doctors at the Weill Cornell Medical College in New York are investigating a treatment for esophagogastric adenocarcinoma that has progressed despite at least 2 methods of therapy. The investigative new therapy, Telomelysin, is a genetically engineered adenovirus to target and infect cancer cells, causing “oncolysis” or the death of cancer cells. In this treatment, the virus will be injected to the tumor along with an IV dose of the FDA-approved drug pembrolizumab, which is an antibody to help the body recognize and fight cancer. Metastatic lesions may also be considered for injection.
The virus is genetically engineered only to cause infection in the cancer cells, and to target features of cancer cells that make them replicate without stopping.
- Be 18 years of age or older
- Have a diagnosis of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
- Must have received at least 2 lines of systemic therapy for advanced disease
- Must agree to contraception during and at least 120 days after the last study dose
- Not be pregnant or breastfeeding
THE STUDY INVOLVES:
- Prescreening tests to confirm eligibility of the patient to participate.
- A single intratumoral (into the tumor) injection of the engineered virus drug every two weeks for 4 total injections, preferably via an endoscopic procedure
- IV infusion of pembrolizumab every 3 weeks
- Follow up will involve visits with X-ray assessments for the first year, and long term follow up continues for 2 years
LOCATIONS AND CONTACTS:
The study site is at Weill Cornell Medical College in New York, NY. Map.
Contact: Sabrina Machado, RN | 646.962.3378 | [email protected]
Weill Medical College of Cornell University
Oncolys BioPharma Inc
Or go online: